Replies to post #48365 on Biotech Values

[drbio45]

I understand the patent on Zyflo expires in 2012. Is that correct? If true, would that alter your favorable outlook for CRTX?

Look at the market cap and 4 years of sales in decent quantities still favors the stock at being cheap. Look what happened to viopharam getting a drug that was losing it patent's sales up.

they are working on an R-isomer which would estend patent situation for them